Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP, Arslan Ö, Demirkan F, Herishanu Y, Ferhanoglu B, Diaz MG, Leber B, Montillo M, Panayiotidis P, Rossi D, Skarbnik A, Tempescul A, Turgut M, Mellink CH, van der Kevie-Kersemaekers AF, Lanham S, Sale B, Del Rio L, Popovic R, Chyla BJ, Busman T, Komlosi V, Wang X, Sail K, Pena GE, Vizkelety T, Forconi F. Kater AP, et al. Among authors: komlosi v. Lancet Oncol. 2024 Apr;25(4):463-473. doi: 10.1016/S1470-2045(24)00070-6. Epub 2024 Mar 8. Lancet Oncol. 2024. PMID: 38467131 Free article. Clinical Trial.
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Manzoor BS, Busman T, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: komlosi v. Leuk Lymphoma. 2023 Aug 25:1-4. doi: 10.1080/10428194.2023.2247511. Online ahead of print. Leuk Lymphoma. 2023. PMID: 37626019 No abstract available.
COVID-19 Breakthrough Infections in Vaccinated Patients With CLL in Israel.
Yekutiel N, Chodick G, Tene L, Bronstein Y, Grunspan M, Rivlin N, Ofek K, Cohen R, Raskin L, Komlosi V, Herishanu Y. Yekutiel N, et al. Among authors: komlosi v. Hemasphere. 2023 Jan 25;7(2):e839. doi: 10.1097/HS9.0000000000000839. eCollection 2023 Feb. Hemasphere. 2023. PMID: 36751514 Free PMC article. No abstract available.
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: komlosi v. Leuk Lymphoma. 2022 Feb;63(2):304-314. doi: 10.1080/10428194.2021.1986217. Epub 2021 Oct 11. Leuk Lymphoma. 2022. PMID: 34632935 Clinical Trial.
11 results